# INTERNATIONAL STANDARD

Third edition 2 017 -03

# Sterilization of health care products — Biological indicators —

# Part 1: General requirements

Stérilisation des produits de santé — Indicateurs biologiques — Partie 1: Exigences générales



Reference number ISO 11138-1:2017(E)



#### © ISO 2017, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

... . . . . . . . . . . . . . <u>ch . de B landonne a romando de B e de B</u> CH-1214 Vernier, Geneva, Switzerland Tel. +41 22 749 01 11 Fax +41 22 749 09 47 copyright@iso.org www.iso.org

# **Contents**





#### **Foreword** Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL:www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 198, Sterilization of health care products.

This third edition cancels and replaces the second edition (ISO 11138-1:2006), which has been technically revised.

A list of all parts of ISO 11138 can be found on the ISO website.

#### <span id="page-4-0"></span>**Introduction** <u>----- - -- -- - -- - --</u>

This document specifies general requirements for production, labelling, test methods and performance requirements for the manufacture of biological indicators including inoculated carriers and suspensions intended for use in validation and monitoring of sterilization processes. Other parts of ISO 11138 provide additional specific requirements for biological indicators for defined sterilization processes.

A graphic description of a biological indicator and its components is presented in Table  $F.1$ . The presentation includes the two types of biological indicators which are covered by ISO 11138 (all parts). This shows that inoculated carriers can be presented directly to the sterilizing agent without prior packaging, or included in a primary package that permits access by the sterilizing agent.

The resistance characteristics depend on the type of test organism, its numbers, the method of preparation, the substrate upon which it is inoculated, environmental conditions during inoculation and drying and the effects of the primary package. Advice on selection, use and interpretation of results of biological indicators can be found in ISO 14161.

For any individual sterilization process, including those covered in relevant parts of ISO 11138, the resistance of the biological indicator will also depend on its microenvironment during testing. In theory, this could lead to an infinite variation in the preparation of biological indicators. Moreover, a ster ilization process could be manipulated in infinite variety to suit each possible set of conditions to which products could be exposed. It has, therefore, been a routine practice to manufacture biological indicators that, when exposed to a set of conditions in a defined sterilization process, provide resistance characteristics expressed as  $D$  values and, where relevant,  $z$  values. Such values are set out in the relevant parts of ISO 11138.

The ISO 11138 series represents the current "state-of-the-art" according to the experts representing manufacturers, users and regulatory authorities involved in developing this document.

Biological indicators for specific sterilization processes not covered by reference test conditions in relevant parts of ISO 11138 should comply with the general requirements in this document, including the resistance testing procedures. Such biological indicators might not be well enough described. or might be used for novel sterilization processes, or might be represented by isolated bioburden microorganisms. If microorganisms other than risk group  $1$  (WHO 2004) are included in these biological indicators, appropriate safety measures (e.g. containment) are necessary.

Standards exist providing requirements for the validation and control of sterilization processes (see Bibliography).

**NOTE** It is possible that some countries or regions have published other standards covering requirements for sterilization or biological indicators (see Bibliography).

### <span id="page-6-0"></span>Sterilization of health care products — Biological indicators indicators —

### Part 1: Part 1 : General requirements

## 1 Scope

This document specifies general requirements for production, labelling, test methods and performance characteristics of biological indicators, including inoculated carriers and suspensions, and their components, to be used in the validation and routine monitoring of sterilization processes.

This document specifies basic and common requirements that are applicable to all parts of ISO 11138. Requirements for biological indicators for particular specified processes are provided in the relevant parts of ISO 11138. If no specific subsequent part is provided, this document applies.

NOTE National or regional regulations can apply.

This document does not apply to microbiological test systems for processes that rely on physical removal of microorganisms, e.g. filtration processes or processes that combine physical and/or mechanical remova l with m icrobio is a late in gradient management as used to infect the infection of the such as team ing and s team ing and s team ing and s team in the such as team ing and such a second ing and so the such a seco of pipe lines. This document, however, can contain elements relevant to such microbiological test systems.

#### $\mathbf{Z}$ Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 11135 , Sterilization of health -care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices

ISO 11737-1:2006, Sterilization of medical devices — Microbiological methods — Part 1: Determination of a population of microorganisms on products

ISO 14937, Sterilization of health care products — General requirements for characterization of a sterilizing agent and the development, validation and routine control of a sterilization process for medical devices

ISO 17665 -1 , Sterilization of health care products — Moist heat — Part 1 : Requirements for the development, validation and routine control of a sterilization process for medical devices

ISO 18472, Sterilization of health care products — Biological and chemical indicators — Test equipment

#### **Terms and definitions** 3

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- IEC Electropedia: available at http://www.electropedia.org/
- ISO Online browsing platform: available at https://www.iso.org/obp/

3 .1

### biological indicator

test system containing viable microorganisms providing a defined resistance to a specified sterilization process

[SOURCE: ISO/TS 11139:2006, 2.3]

#### $3.2$  $-$

carrier

supporting material on or in which test microorganisms are deposited

### 3 .3

### colony forming unit

**CFU**  $$ individual visible units of growth of microorganisms arising from a single cell or multiple cells

### 3 .4

### culture collection number

unique identification of the test organism allocated by a scientifically recognized service culture collection

#### $3.5$  $-5$

### culture conditions

combination of growth media and manner of incubation used to promote germination, growth and/or multiplication of microorganisms

Note 1 to entry: The manner of incubation can include the temperature, time and any other conditions specified for incubation.

[SOURCE: ISO/TS 11139:2006, 2.10]

### 3.6

### D value

### - 10 *va* - 20 va

time or dose required to achieve inactivation of 90  $%$  of a population of the test microorganism under stated conditions

Note 1 to entry: Other critical process variable(s) exhibiting first order inactivation kinetics can achieve an inactivation of 90 % of a population of the test microorganism under stated conditions.

[SOURCE: ISO/TS 11139:2006, 2.11, modified]

### 3 .7

### inactivation

loss of ability of microorganisms to grow and/or multiply

[SOURCE: ISO/TS 11139:2006, 2.21]

## 3 .8

## inoculated carrier

supporting material on or in which a defined number of viable test organisms have been deposited

Note 1 to entry: See Annex F.

## 3 .9

## nominal population

manufacturer's stated number of viable microorganisms

Note 1 to entry. This is generally expressed in log $10$  function (e.g. 10  $^{\circ}$ ).

### 3 .10

#### primary package

element of the packaging system which maintains the integrity of the product

Note 1 to entry: The packaging system protects the inoculated carrier from damage and contamination without preventing penetration of the sterilizing agent.

## 3 .11 process challenge device

**PCD** 

item designed to constitute a defined resistance to a sterilization process and used to assess performance of the process

[SOURCE: ISO/TS 11139:2006, 2.33]

### 3.12

### resistometer

test equipment designed to create defined reference combinations of the physical and/or chemical variables of a sterilization process

[SOURCE: ISO 18472:2006, 3.11, modified]

### $-13$

#### secondary package

container in which biological indicators are packed for transport and storage

#### 3 .14

#### self-contained biological indicator

biological indicator presented in such a way that the primary package, intended for incubation, contains the incubation medium required for recovery of the test organism

### 3.15

### survival-kill window

extent of exposure to a sterilization process under defined conditions where there is a transition from all biological indicators showing growth to all biological indicators showing no growth

### 3 .16

#### survivor curve

graphical representation of the inactivation of a population of microorganisms with increasing exposure to a microbicidal agent under stated conditions

#### 3.17 ---

#### suspension

viable test organisms suspended in a fluid

Note 1 to entry: Suspension can be a biological indicator if ready to use in a sealed glass ampoule or may be an intermediate component used to produce an inoculated carrier or biological indicator.

### 3.18

actual number of recoverable colony-forming units or other appropriate units

Note 1 to entry: See Annex A.

### 3.19

#### <sup>z</sup> value

change in exposure temperature of a thermal sterilization process, which corresponds to a tenfold change in  $D$  value

Note 1 to entry: See ISO 11138 -3 and ISO 11138 -4 .

#### <span id="page-9-0"></span> $\overline{\mathbf{4}}$ 4 General manufacturing requirements

### 4.1 Manufacturing controls

#### **Ouality management systems**  $4.1.1$

A formal quality system (e.g. ISO 13485, GMPs or other national or regional requirements) to cover all operations required by this document shall be established, documented and maintained. In particular, precautions at all stages of production to minimize contamination that would adversely affect the performance of the biological indicator shall be taken.

### 4.1 .2 Traceability

4.1.2.1 Traceability of manufacturing components shall be maintained.

4.1.2.2 Manufacturing components shall include all materials incorporated in, or coming into direct contact with, the test organism suspension, the inoculated carrier and/or its primary package.

### 4.1 .3 Finished product requirements

The finished product shall comply with the following requirements:

- a) labelling  $(4.3)$ ;
- b) manufacturing  $(Clause 5)$ ;
- c) resistance characteristics  $(6.4)$ ;
- d) storage and transport  $(4.4)$ ;
- e) incubation  $(7.3)$ .

NOTE 1 Advice on methods for the use of biological indicators is provided in ISO 14161.

NOTE 2 National and/or regional requirements might exist, for example, in the various national or regional pharmacopoeias .

#### Personnel 4.1.4 4.1 .4 Personnel

The procedures and methods in this document shall be carried out by suitably trained and experienced laboratory personnel (see e.g. ISO 13485).

### 4.2 Test organism

### 4.2.1 Strain

4.2.1.1 Test organisms shall be of a defined strain, available through a recognized culture collection, and shall be identified by appropriate test methods. A statement of traceability shall be provided to the purchaser upon request.

4.2.1.2 The test organism shall be a strain that is

a) suitable for handling without special containment facilities, does not need specific containment procedures for handling and does not have specific transport or mailing requirements (e.g. Risk Group 1, WHO 2004), and

<span id="page-10-0"></span>b) sufficiently stable to maintain its resistance characteristics for the duration of the stated shelf-life when transported and stored in accordance with label directions.

NOTE Traditionally, the test organisms of biological indicators have been bacterial spores, usually derived from Bacillus or Geobacillus species.

4.2.1.3 Test organisms other than bacterial spores may be used if they have been shown to provide appropriate resistance to the sterilization process.

### 4.2 .2 Originating inoculum for suspension

4.2.2.1 The initial inoculum for each batch of test organism suspension shall be

- a) traceable to the reference culture and available through a recognized culture collection, and
- b) verified as to its identity and purity.

The methods used for maintaining test organism cultures shall be designed to protect  $4.2.2.2$ them from contamination and to minimize any induced changes in the inherent properties of the test organisms .

4.2.2.3 Verification tests are specific for each strain of test organism and shall be documented and validated.

### 4.2 .3 Test organism count

The viable test organism count of the suspension shall be determined in accordance with Annex A.

### 4.3 Information to be provided by the manufacturer (labelling)

4.3.1 The following information shall be provided on the label of each individual unit of suspension, inoculated carrier packaging and biological indicator:

- $-$  a unique code by which the manufacturing history can be traced;
- $-$  the name of the test organism:
- $-$  an indication of the sterilization process for which the suspension, inoculated carriers or biological indicators are suitable;
- the expiry date, expressed according to ISO 8601, e.g. YYYY-MM-DD;
- the manufac turer 's name , trademark, address or other means of identi fication .

Internationally recognized symbols may be used where appropriate (see  $4.1.3$ , ISO 15223-1, and ISO 11140-1).

<span id="page-11-0"></span>4.3.2 In addition to the information provided in  $4.3.1$ , the information given in Table 1 shall be provided on or within the secondary packaging of each batch of product.





4.3.3 If a specific instrument is required to detect outgrowth of the biological indicator, the instrument manufacturer shall specify use of that instrument and provide a certificate of calibration and information on the required recalibration procedures.

4.3.4 If applicable, information shall be provided on required maintenance service of the specified instrument including detailed instructions of how to perform the maintenance, service and its frequency.

### 4.4 Storage and transport

4.4.1 Storage and transport conditions for the test organism suspension shall be maintained such that the test organism suspension complies with the requirements of this document and, where relevant. a subsequent part of ISO 11138.

4.4.2 If inoculated carriers are packaged for storage or transport, they shall be packaged in a way that does not adversely affect the nominal population or performance of individual inoculated carriers.

4.4.3 Storage and transport conditions for inoculated carriers shall be maintained such that the inoculated carriers comply with the requirements of this document and where relevant, a subsequent part of ISO 11138.

4.4.4 Individually-packaged biological indicators shall be placed in a secondary package for transport and storage. Packaging for transport and storage shall ensure that biological indicators comply with this document and, where relevant, a subsequent part of ISO 11138.

## <span id="page-12-0"></span>5 Specific manufacturing requirements

### 5 .1 Suspensions

Culture medium and incubation conditions shall consistently produce test organism suspensions  $5.1.1$ that meet the performance requirements of this document and any relevant subsequent part of ISO 11138. <u>. . . . . .</u> . .

**5.1.2** The suspending medium for the test organism suspension shall not adversely affect the stability of the test organism and shall be compatible with the procedures and materials employed in the manufacture of inoculated carriers and biological indicators.

**5.1.3** The method of harvesting and subsequent treatment of suspensions to be used in the inoculation of carriers shall ensure that residues do not adversely influence the performance of the inoculated carrier or biological indicator.

### 5 .2 Carrier, primary and secondary packaging

The materials of the carrier and the primary and secondary packaging shall not contain any  $5.2.1$ contamination (physical, chemical or microbial) that would adversely affect the performance of the biological indicator.

 $5.2.2$ The carrier, the primary and secondary packaging, and the specified storage conditions shall be designed so that the performance characteristics of the biological indicator meet the requirements of this document throughout the stated shelf life of the product. The purchaser shall be provided with a statement of the maximum and minimum values of each dimension of the carrier on request.

5.2.3 During and after the sterilization process, the carrier and the primary packaging shall not retain or release any substance to such an extent that, on transfer to the incubation medium, under the culture conditions, the growth of low numbers of surviving test organisms will be inhibited. Testing shall comply with Annex B.

**5.2.4** The carrier, the primary packaging, and the secondary packaging shall withstand planned transport and handling at the point of use, without damage or breakage.

Raw materials used for the carrier and the primary packaging shall withstand exposure to the  $5.2.5$ sterilization process for which they are intended in such a way that the performance characteristics of the inoculated carrier or biological indicator are maintained. Compliance shall be tested by observation of the carrier and the primary packaging exposed to the extreme ranges and rates of change of the chemical and physical variables of the sterilization process.

**NOTE** Reference sterilization conditions can be found in relevant parts of ISO 11138.

### 5 .3 Inoculated carrier

 $5.3.1$ The inoculated carrier shall be made of materials that will withstand exposure to the sterilization process without distortion, melting, corrosion or other failure that would impair the use of the inoculated carrier.

Only one strain of test organism shall be used in a batch of inoculated carriers, unless the  $5.3.2$ manufacturer has demonstrated that the use of multiple strains does not significantly affect test organism performance in the specified sterilization process.

<span id="page-13-0"></span>**5.3.3** Prior to inoculation, the carrier shall be sterilized in accordance with ISO 17665-1, ISO 11135, and ISO 14937 or other relevant sterilization methods. If sterilization is not practicable, acceptable bioburden limits of the carrier prior to inoculation may be established in accordance with ISO 11737-1:2006. Annex B. 1 : 2006 , Annex B . 2006

**5.3.4** Carriers shall be inoculated so as to maintain a consistent microbial population (see 6.3).

### 5.4 Biological indicators

**5.4.1** Individually packaged biological indicators shall be prepared by placing individual inoculated carriers in a primary pack.

The primary packaging shall be validated for its intended use (see  $\frac{\text{Annex B}}{\text{Denex B}}$ ).  $5.4.2$ 

### 5.5 Self-contained biological indicators

The performance of self-contained biological indicators shall be validated, including the ability of the culture medium to promote growth of the test organisms after being subjected to the sterilization process .

#### 6 Determination of population and resistance 6

### 6 .1 General resistance requirements

6.1.1 The resistance of each lot/batch of biological indicators shall be tested to demonstrate conformance with the performance requirements specified in this document and any relevant subsequent part of ISO 11138.

Resistance characteristics of biological indicators intended for sterilization processes not  $6.1.2$ specified in any subsequent part of ISO 11138 shall be defined using the specific critical variables of that sterilization process (see ISO 14937).

6.1.3 It is recognized that the validation and monitoring of some sterilization processes may use biological indicators that do not meet the minimum population and/or resistance criteria specified in ISO 11138. These biological indicators are acceptable provided that

- a) all other requirements of ISO 11138 (including the method of test for population and resistance) are met,
- b) the product information includes a clear statement of the population and resistance, and
- c) the product label carries a clear warning that the population and/or resistance (as appropriate) is below the value specified in the relevant part of ISO 11138.

6.1.4 Resistance testing shall include determination of the viable count and determination of the resistance characteristics (see  $6.3$  and  $6.4$ ).

### 6 .2 Test organism

The test organism shall be specified (see  $4.2$ ).

### 6 .3 Population of test organisms

**6.3.1** The viable count shall be determined (see  $\frac{\text{Annex A}}{\text{Anex A}}$  $\frac{\text{Annex A}}{\text{Anex A}}$  $\frac{\text{Annex A}}{\text{Anex A}}$ ).

<span id="page-14-0"></span>6 .3 .2 Population verification shall be achieved when results fall within 50 % to 300 % of the manufacturer's stated nominal population . Confirmation test results of the population determined by end users or manufacturers during stated shelf life may meet the 50 % to 300 % range, but could fall below the minimum population specification as defined in this document. In these cases, the original population the minimum population specification as defined in this document. In these cases , the original population is considered to be verified if the confirmation test results are within the 50 % to 300 % range.

### 6 .4 Resistance characteristics

6.4.1 Resistance characteristics shall be determined by a combination of the following methods:

- a) determination of the D value through the construction of a survivor curve (see Annex  $C$ ); or
- b) determination of the D value through a fraction negative method (see [Annex D\)](#page-26-0); and
- c) verification of the survival/kill response characteristics (see  $\triangle$ [Annex E](#page-42-0)).

6.4.2 The values obtained by these methods shall be within the ranges specified in the relevant parts of ISO 11138. At least two of these values shall be included in the labelling of the biological indicators  $(see 4.3).$ 

**6.4.3** The D value shall be within  $\pm 20\%$  of the manufacturer's stated value when determined by the manufacturer during the stated shelf life using the method specified by the manufacturer.

Ideally, the survivor curve is linear over the full range of inactivation. In practice, deviations from this ideal occur, but linearity shall be maintained within acceptable limits. Construction of a survivor curve by enumeration establishes the resistance for surviving populations greater than approximately  $5 \times 10<sup>1</sup>$ , whereas the fraction negative method establishes a statistically based calculation of surviving test organisms below that level. Good correlation of the  $D$  values obtained by the two methods can therefore be used to establish that there are no serious deviations from a linear survivor curve.

Relevant parts of ISO 11138 might require additional determinations [e.g. *z* value for biological indicators for moist heat sterilization (ISO 11138-3) or dry heat sterilization (ISO 11138-4)].

The resistance characteristics specified in this document and any subsequent part of ISO 11138 apply to the specific test conditions stated in those parts.

Confirmation test results of the  $D$  value determined by end users or manufacturers during stated shelf life may meet the  $\pm 20$  % requirement, but could fall below the minimum D value specification as defined in this document. In these cases, the original  $D$  value is considered to be verified if the confirmation test results are within the  $\pm 20$  % range.

6 .4.4 The survivor curve , when p lotted as a semi- logarithmic curve of the log<sup>10</sup> of the viab le test organism count against time, shall be linear with a coefficient of determination,  $r^2$ , of at least 0,8 (see [Annex C](#page-22-0)).

#### $6.5$ **Test conditions** 6 .5 Test conditions

Resistance characteristics and population shall be determined using specified testing conditions (see Table 2).

<span id="page-15-0"></span>

### Table  $2 -$  Minimum test samples according to method

NOTE Common test conditions for specific sterilisation methods have developed over time and are presented in relevant parts of ISO 11138.

<sup>a</sup> The viable count of the unprocessed inoculated carrier or biological indicator.

 $\mathbf{h}$  $\overline{\phantom{a}}$ The extra se t of tes ting cond itions at the exposure sub sequent to t<sup>6</sup> (see [Tab le D .1\)](#page-28-0) is no t used in the ca lcu lations , but is a condition for accepting the test results as valid.

## 7 Culture conditions

### 7 .1 Incubator

**7.1.1** The incubator shall be set to provide, and monitored to confirm, the specified culture conditions.

**7.1.2** In addition to routine monitoring of temperature, the temperature distribution within the incubator shall be validated.

#### 7.2 Growth medium 7 .2 Growth medium

**7.2.1** The growth medium shall be specified and demonstrated to support the growth of an inoculum of less than 100 test organisms.

7.2.2 Labelling shall include information on culture conditions after exposure to the sterilization process (see  $4.3$ ).

**7.2.3** The growth medium shall be validated to ensure that it can neutralize any sterilizing agent residuals that might influence the viability of the test organism (see  $5.2.3$ ).

### 7.3 Incubation

7.3.1 The incubation time and temperature shall be validated.

7.3.2 Instructions for incubation (see Table 1) shall be provided. A reference incubation time is commonly recognized to be seven days for established sterilization processes, such as moist heat and ethylene oxide, using well characterized test organisms, such as *Geobacillus stearothermophilus* and Bacillus atrophaeus, respectively. Where sufficient data are not available to support a reference incubation time of seven days for a novel sterilization method, at least 14 days shall be used as the reference incubation time on which to base the validation.

NOTE 1 It is possible to have a validated incubation time that is shorter than the reference incubation time.

NOTE<sub>2</sub> National or regional requirements for incubation time validation can also exist.

### <span id="page-16-0"></span>7 .4 Software validation

For incubators which incorporate software or which are medical software in themselves, the software shall be validated according to the state of the art taking into account the principles of development lifecycle, risk management, validation and verification.

### 7 .5 Incubation time using detection system

If a specific detection system is to be used with a specific biological indicator, then the combination of the two shall be specified by the manufacturer and used when determining the incubation time.

#### **Annex A** Annex A

## (normative)

#### Determination of viable count Determination of viab le count

### <span id="page-17-0"></span>A.1 General

A.1.1 Enumeration techniques are used to determine the number of viable test organisms in suspension, on inoculated carriers, or from packaged biological indicators, by counting of distinct colony forming units (CFUs). This method is used when the expected number of recoverable test organisms is above  $5 \times 10^1$  CFUs.

A.1.2 The relevant products shall be examined for recoverable test organisms in accordance with A.2 through [A.4.](#page-18-0) This method applies to both processed and unprocessed test samples and can be used for the determination of initial viable count (unprocessed samples) as well as for  $D$  value determination using the survivor curve method (processed samples).

A.1.3 Alternative methods of enumeration with demonstrated equivalence to direct plating techniques may be used.

### A.2 Minimum number of test samples

A minimum of four test samples from each lot/batch or exposure shall be used.

### A.3 Sample preparation and culture methods

**A.3.1** The test samples shall be placed in an appropriate volume of suspending medium. The test organisms shall be eluted from the test samples by a validated procedure (e.g. maceration with glass beads, grinding and/or blending in a homogenizer and/or blender, vortexing, ultrasonication or other appropriate procedure). See ISO 11737-1.

A.3.2 The concentration of microorganisms in the suspensions shall be adjusted by dilution, if necessary, in appropriate sterile dilution fluid . Numbers of CFUs should be within a specified range for the method used whenever possible.

For cultures poured into molten agar or spread on solidified agar in regular size Petri dishes, numbers of CFUs between 30 and 300 are considered to be the most accurate.

**A.3.3** An appropriate method for the enumeration of viable organisms shall be used.

Appropriate methods include membrane filtration techniques, direct spreading on semi-solid agar growth medium or mixing with molten tempered agar growth medium (see ISO 11737-1).

A.3.4 The biological indicator manufacturer shall identify or make available a suitable medium for recovery of test organisms and/or complete data and instructions for the preparation of such a medium.

### <span id="page-18-0"></span>A.4 Incubation and enumeration

A.4.1 The plated samples or the membrane filters shall be incubated at temperatures and times specified by the manufacturer.

In general, the incubation times and temperatures are 55 °C to 60 °C for not less than 48 h for thermophilic microorganisms and 30 °C to  $37$  °C for not less than 48 h for mesophilic microorganisms.

NOTE Desiccation of the growth medium can adversely affect growth at elevated incubation temperatures.

A.4.2 After the appropriate incubation time, the numbers of colony forming units on the plates or membrane filters shall be counted and the mean number of recoverable test organisms per appropriate unit shall be calculated.

#### **Annex B** Annex B

## (normative)

# <span id="page-19-0"></span>Determination of growth inhibition by carriers and primary packaging materials exposed to sterilization processes

### **B.1 Principle**

This method is used to determine the suitability of the carrier and primary packaging materials for the intended sterilization process by identifying possible inhibitory effects of these materials on growth of the test organisms after sterilization. The physical properties of these materials shall have already been tested for suitability (see  $\frac{5.2}{1.2}$  and  $\frac{5.3}{1.8}$ ). Test methods are given in relevant parts of ISO 11138. Specifications for resistometers are given in ISO 18472.

## **B.2** Materials

**B.2.1** A suspension of test organisms of the same strain shall be prepared in the same manner as the organisms to be used for inoculation of carriers. The suspension shall be of known population, as determined by viable count, to permit dispensing of test samples with a population of less than 100 viable organisms.

**B.2.2** The incubator shall be set to provide, and monitored to confirm, the temperature specified in the culture conditions.

 $R.2.3$ The growth medium shall be as specified in the culture conditions.

**B.2.4** Test samples shall be uninoculated carriers or primary packaging materials prepared in accordance with B.3. accordance with B .3 .

## **B.3 Procedure**

**B.3.1** Prepare fifteen containers of growth medium and equilibrate to the incubation temperature specified in the culture conditions. Use the same volume of growth medium as typically used for the suspension, inoculated carrier or biological indicator.

**B.3.2** Take a representative sample of eighteen previously sterilized uninoculated carriers and divide the carriers into nine groups of two. They shall be packaged in the material used in the manufacture of the biological indicators.

NOTE If sterilization is not practicable, see  $5.3.3$ .

**B.3.3** Take six groups of the carriers from the sample taken in  $B.3.2$ , each containing two carriers, and then expose them to the sterilization process.

**B.3.4** Set the operational conditions of the resistometer to the values specified in the relevant parts of ISO 11138, as appropriate.

B.3.5 At the end of the process, unwrap the carriers and aseptically transfer them to the growth medium without subjecting them to intermediate treatment. Place the contents of one group of two <span id="page-20-0"></span>carriers into each of the six containers of growth medium previously equilibrated to the incubation temperature (see  $\underline{B.3.1}$ ). Record the time taken to complete the transfer.

**B.3.6** Incubate the growth medium containing the carrier samples at the specified temperature for  $2 h \pm 10$  min to allow any inhibitory substances to desorb from the carriers. Remove the growth medium from the incubator and inoculate each container with a volume of the test organism suspension calculated to contain less than 100 test organisms . Return the inoculated medium to the incubator. Incubate for the validated time period specified for recovery of biological indicators under normal conditions of use.

**B.3.7** Control is performed by transferring the three remaining groups of two carriers, not exposed to the process , to the three remaining containers of incubation medium . Incubate these containers for  $2 h \pm 10$  min, then inoculate each container with less than 100 test organisms, and incubate them for the specified incubation time in the same manner as described in  $B.3.6$ .

**B.3.8** Microorganism identification may be performed if the use of non-sterile carriers is suspected of influencing the test results.

**B.3.9** For growth medium controls, incubate three containers of growth medium, without carriers, for 2 h  $\pm$  10 min. Then inoculate each container with less than 100 test organisms and incubate for the specified incubation time in the same manner as described in B.3.6.

B.3.10 The remaining three containers of growth medium are used as negative media controls. Incubate these non-inoculated media containers for the validated time period specified for recovery of biological indicators under normal conditions of use.

## **B.4** Interpretation of results

B.4.1 If "no growth" occurs in one or more of the growth media controls, the test procedure shall not be regarded as valid .

"No growth" in the growth media controls can be indicative of failure to control the population of the **NOTE** test organism inoculum or of inappropriate recovery conditions (i.e. growth medium, incubation time, incubation temperature etc.).

**B.4.2** If "no growth" occurs in one or more of the carrier controls, the carrier shall not be regarded as suitable for the manufacture of inoculated carriers or biological indicators.

**NOTE** "No growth" in the carrier control where growth occurred in the growth medium can indicate that the carrier material is inhibitory to the growth of the test organism.

**B.4.3** If "no growth" occurs in one or more of the six tests of carriers exposed to the sterilization process, the carrier material shall not be regarded as suitable for the manufacture of inoculated carriers or biological indicators.

**NOTE** "No growth" can be caused by either high levels of absorption of sterilant or by degradative changes in the carrier material during the sterilization process.

**B.4.4** If "growth" occurs in one or more of the negative media controls, the test procedure shall not be regarded as valid.

NOTE "Growth" in the negative media control could indicate that the media samples have been contaminated.

## B .5 Determination of growth inhibition by primary packaging materials

**B.5.1** Samples of the primary packaging material shall be tested in a similar way as the carrier material (i.e. follow steps  $\underline{B.1}$  through  $\underline{B.4}$  using the primary packaging materials as the test samples).

**B.5.2** The test shall be carried out using samples of primary packaging material equivalent to twice the area normally in contact with the inoculated carrier, or for self-contained biological indicators, equivalent to the area normally in contact with the recovery medium. The test samples shall be immersed in the growth medium .

#### **Annex C** Annex C (normative)

# <span id="page-22-0"></span><sup>D</sup> value determination by survivor curve method

## C.1 Principle

This method determines the number of surviving test organisms by direct counting of colony forming units (CFUs). This method is also referred to as the "direct enumeration method". See also Annex A.

NOTE The method has a practical lower limit of approximately  $5 \times 10^1$  CFUs.

### C.2 Materials

**C.2.1** Test samples representing spore suspensions, inoculated carriers or packaged biological indicators shall be included in the materials. A minimum of 20 test samples are required for this method.

NOTE Test methods are given in relevant parts of ISO 11138. Specifications for resistometers are given in ISO 18472 .

The incubator shall be set to provide, and monitored to confirm, the temperature specified in the  $C.2.2$ culture conditions .

 $C.2.3$ The growth medium as specified in the culture conditions shall be included in the materials.

#### C.3 Procedure C .3 Procedure

**C.3.1** Test samples shall be subjected to defined exposure conditions. The range of exposures shall be stated. See Table 2

**C.3.2** A minimum of five exposures shall be used and shall include

a) one exposure in which the sample is not subjected to the sterilant (e.g. 0 time exposure),

NOTE The sterilant can be absent or replaced by an inert gas or medium.

- b) at least one exposure in which the viable population is reduced to 0,01 % of the original inoculum  $\mathbf{y} = -\mathbf{y} - \mathbf{y}$
- c) a minimum of three exposures covering the intervals between exposure a) and exposure b) above.

Not less than four test samples shall be used for each exposure in each determination. The same  $C.3.3$ number of replicates shall be used for each exposure.

**C.3.4** If the sterilizing agent leaves a residue in or on the test samples, this shall be neutralized as rapidly as possible so as not to interfere with the test results. If a neutralization procedure is required, it shall be validated.

 $C.3.5$ Within 2 h of each exposure, the test samples shall be treated to remove the test organisms from the carrier and a viable count assay performed (see  $\Delta$ nnex  $\Delta$ ) using the specified culture conditions and methods stated by the manufacturer for recovery under normal conditions for use .

<span id="page-23-0"></span>**C.3.6** The suspensions shall be adjusted in appropriate sterile dilution fluid. For cultures poured into molten agar or spread on solidified agar in regular size Petri dishes, numbers of colony forming units between  $30$  and  $300$  are considered to be statistically valid.

C .3 .7 Us ing all the data obtained , p lot the log<sup>10</sup> of the surviving population against exposure time in minutes, dose level or other process variable and determine the best-fit rectilinear curve by regression analysis using the method of least squares. Survivor data points within 0,5 logarithms of the initial population shall not be included in the regression analysis. Calculate the negative reciprocal of the slope of the line obtained, which is equal to the  $\overline{D}$  value in minutes, dose level or other process variable at the stated exposure conditions.

The slope of the best-fit rectilinear curve is calculated using Formula  $(C.1)$ : a)

$$
m = \frac{(nG) - (AB)}{(nC) - (A^2)}
$$
(C.1)

 $\cdots$  where  $\cdots$ 

- $m$  is the slope of the best-fit rectilinear curve;
- $n$  is the number of data points;

$$
G = \sum [t (\log_{10} y)].
$$
  
\n
$$
A = \sum (t);
$$
  
\n
$$
B = \sum (\log_{10} y);
$$
  
\n
$$
C = \sum (t^2).
$$

An example of regression analysis is given in Table C.1.





<span id="page-24-0"></span>b) Example calculations for the slope of the best-fit rectilinear curve are found in Table C.2 and below.

Recovered populationa	<b>Exposure</b> condition (minutes or other critical parameter) t <sub>b</sub>	$log_{10}y$	$t^2$	$t(\log_{10}y)$	$(log_{10}y)^2$	
$y_1 = 2.5 \times 10^6$	$t_1 = 0,0$	$log_{10}y_1 = 6,3979$	$(t_1^2) = 0$	$t_1(\log_{10}y_1)=0$	$(\log_{10}y_1)^2 = 40,9331$	
$y_2 = 3.4 \times 10^5$	$t_2 = 2,0$	$log_{10}y_2$ = 5,531 5	$(t22) = 4$	$t_2(\text{log}_{10}y_2) = 11,063$ 0	$(\log_{10}y_2)^2 = 30,5975$	
$y_3 = 3.1 \times 10^4$	$t_3 = 4.0$	$log_{10}y_3 = 4,4914$	$(t_3^2) = 16$	$t_3(log_{10}y_3) = 17,9656$	$(\log_{10}y_3)^2 = 20,1727$	
$y_4 = 1.7 \times 10^3$	$t_4 = 6,0$	$log_{10}y_4 = 3,2304$	$(t_4^2) = 36$	$t_4(\text{log}_{10}y_4) = 19,3824$	$(log_{10}y_4)^2 = 10,4355$	
$y_5 = 1.9 \times 10^2$	$t_5 = 8.0$	$log_{10}y_5 = 2,2788$	$(t_5^2) = 64$	$t_5(\text{log}_{10}y_5) = 18,2304$	$(\log_{10}y_5)^2 = 5,1929$	
	$A = \sum_{i=1}^{i=5} t_i$ $i=1$	$B = \sum_{i=5}^{i=5} \log_{10} y_i$	$C = \sum_{i=5}^{i=5} (t_i)^2$	$G = \sum_{i=0}^{i=5} \left[ t_i \left( \log_{10} y_i \right) \right]$	$E = \sum_{i=5}^{i=5} (\log_{10} y_i)^2$	
Assigned variable	$A = 20$	$B = 21,9300$	$C = 120$	$G = 66,6414$	$E = 107,3317$	
According to $C.3.7$ Data points within 0,5 logarithms of $y_1$ shall not be included in the regression analysis. a l b Any critical process parameter, e.g. time $(t)$ .						

Table  $C.2$  - Examples of calculations for slope

$$
m = \frac{(nG) - (AB)}{(nC) - (A^2)}
$$
  
\n
$$
m = \frac{\left[ (5)(66, 641 \cdot 4) \right] - \left[ (20)(21, 930 \cdot 0) \right]}{\left[ (5)(120) \right] - (20^2)}
$$
  
\n
$$
m = \frac{(333, 207 \cdot 0) - (438, 600 \cdot 0)}{(600) - (400)}
$$
  
\n
$$
m = \frac{-105, 393 \cdot 0}{200}
$$
  
\n
$$
m = -0, 527 \cdot 0
$$

c) The  $D$  value is equal to the negative reciprocal of the slope obtained and is calculated using Formula (C.2):

$$
D \text{ value} = -1 \left( \frac{1}{m} \right) \tag{C.2}
$$

Using the above calculated slope, the resulting  $D$  value is:

$$
D = -1 \left( \frac{1}{-0,527 \text{ o}} \right) = 1,897 \text{ 5 min (rounded to one decimal place } D = 1,9 \text{ min})
$$

### ISO 11138-1 :2017(E)

**C.3.8** The value obtained for the coefficient of determination,  $r^2$ , for the linearity of the survivor curve shall be not less than 0,8.

a) The coefficient of determination,  $r^2$ , for the linearity of the survivor curve is calculated using Formula (C.3)

$$
r^2 = \frac{\left\{ (G) - \left[ (A) (B/n) \right] \right\}^2}{\left[ (C) - \left( A^2/n \right) \right] \left[ (E) - \left( B^2/n \right) \right]}
$$
(C.3)

where a line construction in C . and E .  $\frac{1}{2}$  .  $\frac{1}{2}$  ,  $\frac{1}{2}$  ,  $\frac{1}{2}$  ( $\frac{1}{2}$   $\frac{1}{0}$   $\frac{1}{2}$ )

b) Example calculations for the coefficient of determination,  $r^2$ , for the linearity of the survivor curve Using the values from Table C.2:

$$
r^{2} = \frac{\left[ (66,6414) - \left[ (20) (21,9300/5) \right] \right]^{2}}{\left[ (120) - (20^{2}/5) \right] \left[ (107,3317) - (21,9300^{2}/5) \right]}
$$
  

$$
r^{2} = \frac{\left[ (66,6414) - (87,7200) \right]^{2}}{\left[ (120) - (80) \right] \left[ (107,3317) - (96,1850) \right]}
$$
  

$$
r^{2} = \frac{\left[ -21,0786 \right]^{2}}{\left[ 40 \right] \left[ 11,1467 \right]}
$$
  

$$
r^{2} = \frac{444,3074}{445,8680}
$$
  

$$
r^{2} = 0,9965
$$

#### **Annex D** Annex D (normative)

# <span id="page-26-0"></span><sup>D</sup> value determination by fraction negative method

## D.1 Principle

**D.1.1** This method determines the number of surviving test organisms by indirect calculation based on the recoverable number of microorganisms as determined by visual observation of growth in fluid growth medium. The method referred to as "fraction negative analysis" is a method in which a fraction of the test samples shows no growth (the fraction negative range) and the calculation is based on the results obtained with this data. A "total kill analysis" is also a fraction negative method in which all the test samples show no growth and the calculation is based on the results obtained with this requirement. This method is used when the recoverable number of test organisms is less than 5 CFUs/unit of measure.

**D.1.2** The Holcomb-Spearman-Karber procedure (see D.3.1) and Limited-Holcomb-Spearman-Karber procedure (see  $D(3.2)$ ) require successive exposures which span the fraction negative range.

NOTE Other methods can be applicable, particularly when the survival-kill window is known. One such alternative method is provided by the Stumbo-Murphy-Cochran procedure (see D.3.3).

**D.1.3** Test samples shall be subjected to defined exposure conditions remaining within a defined window (steady-state), except the process variable used to calculate the  $D$  value. Where the process variables are considered to be acceptably narrow, time is expressed as " $t$ ". Where the control of process variables is too wide to be considered constant, methods of integration may be used to calculate equivalent time " $U$ ". Both terms are found in the literature.

NOTE In the following subclauses and formulae of this annex, the variable " $t$ " can be replaced by any other process variable used to calculate the  $D$  value.

**D.1.4** The number of samples exposed,  $n$ , in each exposure and the intervals between sequential exposures,  $d$ , both affect the reliability of the test.

#### **D.2** Materials <u>2002 - 2002 - 2002 - 200</u>

**D.2.1** Test samples shall be representative of spore suspensions, inoculated carriers or packaged biological indicators.

 $D.2.2$ The relevant resistometer shall be used. D.2 .2 The re levant res istometer shal l be used .

**NOTE** Test methods are given in relevant parts of ISO 11138. Specifications for resistometers are given in the ISO 18472 . In the ISO 1847

**D.2.3** The incubator shall be set to provide, and monitored to confirm, the temperature specified in the culture conditions.

**D.2.4** The growth medium shall be as specified in the culture conditions.

## <span id="page-27-0"></span>D.3 Procedure

### D.3 .1 Holcomb-Spearman-Karber procedure (HSKP)

### D.3.1.1 Procedure

**D.3.1.1.1** Test samples shall be subjected to graded exposures to the defined exposure conditions with all process variables, except time, remaining constant. The total number of test samples shall be not less than 100. The minimum number of 20 replicates shall be used for each exposure.

**D.3.1.1.2** A minimum of five exposure conditions shall be used including at least one set of samples in which all test samples show growth, two sets of samples in which a fraction of the test samples show growth, and two sets of test samples, from sequential exposures, in which no growth is observed.

NOTE Details of requirements for specific resistometer process parameters are provided in relevant parts of ISO 11138.

**D.3.1.1.3** When the sterilizing agent leaves a residue in or on the test samples, this shall be neutralized as rapidly as possible so as not to interfere with the test results. If a neutralization procedure is required, it shall be validated.

D.3.1.1.4 Samples shall be cultured after exposure according to the manufacturer's specified method.

**D.3.1.1.5** Each inoculated carrier is transferred aseptically to a test tube containing an adequate volume of the specified growth medium. The volume of medium shall be the same for each replicate. The manufacturer of the biological indicators shall identify or make available a suitable recovery medium and/or the complete data for preparing one (see also  $4.3$ ). If the growth medium is included by the manufacturer as an integral part of the biological indicator, the manufacturer's culturing instructions shall be followed.

**D.3.1.1.6** The test samples shall be incubated following the manufacturer's specified methods. The cultures shall be examined after the manufacturer's recommended incubation time or validated incubation time period (see  $7.3$ ). Growth of the test organism can be indicated by turbidity of the broth medium, growth on the surface of the broth, or sediment at the bottom of the tube, depending upon the characteristics of the test organism and broth medium . If the growth medium is an integral part of the biological indicator, e.g. self-contained biological indicators, growth or no growth of the test organism might be indicated by a pH color change, and shall be interpreted according to the manufacturer's instructions. instructions .

**D.3.1.1.7** The results are recorded as the ratio of inoculated carriers with non-recoverable test organisms to the total number of inoculated carriers tested at each sub-lethal exposure.

### D.3.1.2 Calculations using the HSKP

**D.3.1.2.1** The calculations are based on a minimum of five exposure conditions and shall include at least

- one set of samples in which all tested samples show growth,
- two sets of samples in which a fraction of the samples shows growth, and
- two sets of samples, from sequential exposures, in which no growth is observed (see Table D.1).

NOTE HSKP is similar to the Limited Holcomb-Spearman-Karber procedure (see  $D.3.2$ ), except that it uses a generic formula which is not limited to the same number of replicates at each exposure condition or constant time intervals between exposures.

<span id="page-28-0"></span>**D.3.1.2.2** The average *D* value is calculated using Formula  $(D.1)$ :

$$
D = \frac{U_{\text{HSK}}}{\log_{10} N_0 + 0.250 \text{ 7}} \tag{D.1}
$$

where

$$
U_{\text{HSK}} = \sum_{i=1}^{k-1} U_i
$$

- $N<sub>0</sub>$ is the average viable count per indicator determined by the total viable count method (see [Annex A\)](#page-17-0);
- $U_i$ is the *ith* treatment time;
- $k$  is the first exposure point with all units negative.

The data required for the calculation are given in **Table D.1**.

Time of exposure to sterilizing agent (min)	<b>Number of test samples</b> exposed	Number of test samples showing no growth
	$\boldsymbol{n}$	r
$t_1$ (U <sub>1</sub> )	n <sub>1</sub>	$r_1(r=0)$ <sup>a</sup>
$t_2$	n <sub>2</sub>	r <sub>2</sub>
$t_3$	$n_3$	$r_3$
$t_4$	$n_4$	$r_4$
$t_5(U_{k-1})$	n <sub>5</sub>	r <sub>5</sub>
$t_6$ (U <sub>k</sub> )	$n_6$	$r_6(r = n_6)$
$t_7$	n <sub>7</sub>	$r_7(r = n_7)$ a

Table  $D.1$  - Examples of data collected for HSKP

NOTE t<sup>1</sup> is defined as the longes t exposure time to the s ter i l iz ing agent in the expo sure se t where a l l tes t samp les show growth . E xpo sure the fraction that is also are increased the fraction the fraction of the fraction of  $\mu$  and t are two sequential exposure times at which all samples show no growth.

The test is valid if there are no negative units, i.e. no negative test samples  $(r = 0)$ , with all units showing growth at the exposure preceding in and an industrie tes to an library (r = n7) ) , i .e . none show in .e . none show in the exposure sub sequent to t

D.3 .1 .2 .3 For times of exposure to steril izing agent, t<sup>1</sup> to t6, the factors χ and γ are calculated as shown :

$$
\chi_{i} = \frac{t_{i} + t_{(i+1)}}{2}
$$

$$
\gamma_{i} = \frac{r_{i+1}}{2} - \frac{r_{i}}{2}
$$

 $r_{i+1}$  i

 $\cdots$   $\cdots$   $\cdots$   $\cdots$ 

- $\mathbf{r}_i$  , as an exposure to the teamples showing no growth at an exposure time  $\mathbf{r}_i$
- nis the statement of the statement to the s term in the s term in large to the statement at exposure time the

 $\mathcal{L}_{1}$ , and the complete show growth and so  $\mathcal{L}_{l}$ <sup>r</sup>

From the ca lcu lated va lues of <sup>χ</sup><sup>i</sup> and γ<sup>i</sup> above , the va lue U<sup>i</sup> can be ca lcu lated for each exposure time , t<sup>i</sup> , as follows: as fo l lows :

$$
U_i = \chi_i \, \gamma_i
$$

 $\mathcal{L}$  . 2 . 2 .4 The mean time time to steril ity, from any of the test samples samples as the canonical theories sum of U<sup>i</sup> for each exposure time t<sup>1</sup> to t6:

$$
U_{\text{HSK}} = \sum_{i=1}^{i=6} U_i
$$

**D.3.1.2.5** Where the interval between exposure times,  $d$ , is constant and the same number of test samp les , n, is used at each exposure time , the mean to steril ity, UHSK, can be calculated us ing Formula (D.2):

$$
U_{\text{HSK}} = U_{\text{K}} - \frac{d}{2} - \frac{d}{n} \sum_{i=1}^{i=6} r_i
$$
 (D.2)

where

 $\mathbb{E} \mathbf{N}$  is the first time  $\mathbf{N}$  is are negative  $\mathbf{N}$  and  $\mathbf{N}$  is are negative ;

 $d$  is the exposure interval.

**D.3.1.2.6** The mean *D* value, *D*, can be calculated using Formula  $(D.3)$ :

$$
\overline{D} = \frac{U_{\text{HSK}}}{\log_{10} N_0 + 0.250 \, 7} \tag{D.3}
$$

NOTE 1 The Euler constant =  $0,577$  2.

NOTE 2  $0,577 \frac{2}{\ln 10} = 0,250 \frac{7}{10}$ .

where

 $N_0$ is the initial viable count of test organisms per test sample (see  $\frac{\text{Annex A}}{\text{Anex A}}$  $\frac{\text{Annex A}}{\text{Anex A}}$  $\frac{\text{Annex A}}{\text{Anex A}}$ ).

 $D=1$  . The state  $\alpha$  is confidence interval for  $D=1$  ,  $p$  ,  $\alpha$  ,  $p$  is calculated using <u>Formula (D .4)</u> :

$$
D_{\text{calc}} = \overline{D \pm 2\sqrt{V}} \tag{D.4}
$$

**D.3.1.2.8** The variance, *V*, is calculated using Formula  $(D.5)$ .

$$
V = a \left( \frac{2,302 \text{ } 6}{\ln N_0 + 0,577 \text{ } 2} \right)^2 \tag{D.5}
$$

**D.3.1.2.9** The " $a$ " for the variance is calculated using Formula  $(D.6)$ :

$$
a = 0.25 \sum_{i=2}^{i=6} \left[ t_{(i+1)} - t_{(i-1)} \right]^2 \left[ r_i \frac{(n_i - r_i)}{n_i^2 (n_{i-1})} \right]
$$
(D.6)

### D.3.1.3 Example calculation of the Holcomb-Spearman-Karber procedure (HSKP)

Examples of calculation of the HSKP are given in Table D.2.

### Table D.2 – Examples of data with non-constant time intervals and non-constant number of samples



D.3 .1 .3 .1 Calculate χ<sup>i</sup> and γ<sup>i</sup> (for each exposure) :

$$
\chi_{i} = \frac{t_{i} + t_{(i+1)}}{2}
$$
\n
$$
\chi_{1} = \frac{t_{1} + t_{(1+1)}}{2}
$$
\n
$$
\chi_{1} = \frac{10 + 18}{2} = 14
$$
\n
$$
\chi_{2} = \frac{18 + 28}{2} = 23
$$
\n
$$
\chi_{3} = \frac{28 + 40}{2} = 34
$$
\n
$$
\chi_{4} = \frac{40 + 50}{2} = 45
$$
\n
$$
\chi_{5} = \frac{50 + 60}{2} = 55
$$
\n
$$
\chi_{6} = \frac{60 + 70}{2} = 65
$$
\n
$$
\gamma_{i} = \frac{r_{i+1}}{n_{i+1}} - \frac{r_{i}}{n_{i}}
$$

$$
\gamma_1 = \frac{r_{1+1}}{n_{1+1}} - \frac{r_1}{n_1}
$$
  
\n
$$
\gamma_1 = \frac{4}{19} - \frac{0}{20} = 0.21
$$
  
\n
$$
\gamma_2 = \frac{8}{21} - \frac{4}{19} = 0.17
$$
  
\n
$$
\gamma_3 = \frac{12}{20} - \frac{8}{21} = 0.22
$$
  
\n
$$
\gamma_4 = \frac{16}{20} - \frac{12}{20} = 0.2
$$
  
\n
$$
\gamma_5 = \frac{20}{20} - \frac{16}{20} = 0.2
$$
  
\n
$$
\gamma_6 = \frac{20}{20} - \frac{20}{20} = 0
$$

---

NOTE For the case can latin and γγγγια γγ− , both γ γ−. The number of the number of the number of tes t sample show in company in a galaxy increase at a construction in the construction in the second construction in the s

D.3 .1 .3 .2 Calculate U<sup>i</sup> for each exposure time , t<sup>i</sup> :

$$
U_i = \chi_i \gamma_i
$$
  
\n
$$
U_1 = \chi_1 \gamma_1 = 14 \times 0.21 = 2.94
$$
  
\n
$$
U_2 = 23 \times 0.17 = 3.91
$$
  
\n
$$
U_3 = 34 \times 0.22 = 7.48
$$
  
\n
$$
U_4 = 45 \times 0.2 = 9.0
$$
  
\n
$$
U_5 = 55 \times 0.2 = 11.0
$$
  
\n
$$
U_6 = 65 \times 0 = 0
$$

 $-$  0  $-$  0

D.3 .1 .3 .3 The mean time to steril ity, UHSK, is calculated us ing Formula (D .7 ) :

$$
U_{\text{HSK}} = \sum_{i=1}^{i=6} \mu_i
$$
\n
$$
U_{\text{HSK}} = \mu_1 + \mu_2 + \mu_3 + \mu_4 + \mu_5 + \mu_6
$$
\n
$$
U_{\text{HSK}} = 2,94 + 3,91 + 7,48 + 9,0 + 11,0 + 0 = 34,33
$$
\n
$$
(D.7)
$$

**D.3.1.3.4** The mean *D* value, *D*, is calculated using Formula  $(D.8)$ :

$$
\overline{D} = \frac{U_{\text{HSK}}}{\log_{10} N_0 + 0.250 \text{ 7}} \tag{D.8}
$$

where

 $W_0$  is the initial population of  $1 \wedge 10^{-1}$ 

$$
D = \frac{34,33}{5,000 + 0,250 \text{ 7}} = 6,54 \text{ min.}
$$

D.3 .1 .3 .5 The 95 % confidence interval for D (p = 0 ,05 ) , Dcalc, is calculated us ing Formula (D .9 ) :

$$
D_{\text{calc}} = \overline{D} \pm 2\sqrt{V} \tag{D.9}
$$

**D.3.1.3.6** The variance, *V*, is calculated using **Formula**  $(D.10)$ :

$$
V = a \left( \frac{2,302 \text{ } 6}{\ln N_0 + 0,557 \text{ } 2} \right)^2 \tag{D.10}
$$

D.3 .1 .3 .7 The "a" in the variance formula for each t<sup>i</sup> and summing al l results is calculated us ing Formula (D.11):

$$
a = 0.25 \sum_{i=2}^{i=6} \left\{ \left[ t_{(i+1)} - t_{(i-1)} \right]^2 \left[ r_i \frac{n_i - r_i}{n_i^2(n_i - 1)} \right] \right\}
$$
  
\n
$$
a = 0.25 \left\{ (t_{1+1} - t_{1-1})^2 \left[ r_1 \frac{n_1 - r_1}{n_1^2(n_1 - 1)} \right] + (t_{2+1} - t_{2-1})^2 \left[ r_2 \frac{n_2 - r_2}{n_2^2(n_2 - 1)} \right] + (t_{3+1} - t_{3-1})^2 \left[ r_3 \frac{n_3 - r_3}{n_3^2(n_3 - 1)} \right] \right\}
$$
  
\n
$$
+ (t_{4+1} - t_{4-1})^2 \left[ r_4 \frac{n_4 - r_4}{n_4^2(n_4 - 1)} \right] + (t_{5+1} - t_{5-1})^2 \left[ r_5 \frac{n_5 - r_5}{n_5^2(n_5 - 1)} \right] + (t_{6+1} - t_{6-1})^2 \left[ r_6 \frac{n_6 - r_6}{n_6^2(n_6 - 1)} \right] \right\}
$$
  
\n
$$
a = 0.25 \times \left[ (28 - 10)^2 \times 4 \left( \frac{19 - 4}{361 \times 18} \right) = 2.9917 +
$$
  
\n
$$
(40 - 18)^2 \times 8 \left( \frac{21 - 8}{441 \times 20} \right) = 5.7070 +
$$
  
\n
$$
(50 - 28)^2 \times 12 \left( \frac{20 - 12}{400 \times 19} \right) = 6.1137 +
$$
  
\n
$$
(60 - 40)^2 \times 16 \left( \frac{20 - 16}{400 \times 19} \right) = 3.3684 +
$$
  
\n
$$
(70 - 50)^2 \times 20 \left( \frac{20 - 20}{400 \times 19} \right) = 0,0000 \text{ J}
$$
  
\n
$$
a = 0.25 \left[ 2.9917 + 5.7070 + 6.1137 + 3.3
$$

### ISO 11138-1 :2017(E)

 $a = 0.25 \times 18,180$  8 = 4,545 2

**D.3.1.3.8** The variance, *V*, is calculated using **Formula (D.12)** now that " $a$ " is calculated:

$$
V = a \left( \frac{2,302 \text{ } 6}{\ln N_0 + 0,577 \text{ } 2} \right)^2 \tag{D.12}
$$

where

N<sup>0</sup> = 1 × 10<sup>5</sup>;

$$
V = 4,545 \ 2 \left[ \frac{2,302 \ 6}{\ln(1 \times 10^5) + 0,577 \ 2} \right]^2
$$
  
= 4,545 \ 2 \left( \frac{2,302 \ 6}{11,513 + 0,577 \ 2} \right)^2  
= 4,545 \ 2 \times (0,190 \ 45)^2  
= 4,545 \ 2 \times 0,036 \ 27;  

$$
V = 0,164 \ 9.
$$



$$
D_{\text{calc}} = \overline{D} \pm 2\sqrt{V} \tag{D.13}
$$

### D.3.1.3.10 Lower confidence limit:

$$
D_{\text{calc}} = \overline{D} - 2\sqrt{V}
$$
  
= 6,54 - 2 \sqrt{0,164.9}

 $= 6,54 - (2 \times 0,4061) = 5,73$ 

D.3.1.3.11 Upper confidence limit:

$$
D_{\text{calc}} = \overline{D} + 2\sqrt{V}
$$
  
= 6,54 + 2\sqrt{0,1649}  
= 6,54 + (2 \times 0,4061) = 7,35

### <span id="page-34-0"></span>D.3 .2 Limited Holcomb-Spearman-Karber procedure (LHSKP)

### D.3.2.1 Calculations using LHSKP

**D.3.2.1.1** The calculations for LHSKP are based on a minimum of five exposure conditions and shall include at least

- $-$  one set of samples in which all tested samples show growth,
- $-$  two sets of samples in which a fraction of the samples shows growth, and
- two sets of samples in which no growth is observed (see Table D.3).

**D.3.2.1.2** LHSK procedure is similar to HSKP (see  $D.3.1$ ), except that it uses a formula which requires the same number of replicates at each exposure condition and constant time intervals between exposures.

Table D.3 – Examples of data collected for LHSKP with constant time intervals and constant number of samples

<b>Exposure time to sterilizing agent</b> Number of test samples exposed		Number of test samples showing
min		negative results
	n	$r_i$
$t_{1}\,(U_{1})$	$n_1$	$r_1(r = 0)$
$t_2$	n <sub>2</sub>	r <sub>2</sub>
$t_3$	$n_3$	$r_3$
$t_4$	$n_4$	$r_4$
$t_{5}(U_{k-1})$	n <sub>5</sub>	r <sub>5</sub>
$t_6(U_k)$	$n_{6}$	$r_6(r = n)$
$t_7$	n <sub>7</sub>	$r_7(r = n)$ a
	$\mathcal{L} = \mathcal{L} = \mathcal$	$\mathbf{1}$ , $\mathbf{1}$ , $\mathbf{1}$ , $\mathbf{1}$ , $\mathbf{1}$ , $\mathbf{1}$ , $\mathbf{1}$

The test the state is varied and indicated under the construction of  $\mathbf{u}$  ,  $\mathbf{u}$  is varied in  $\mathbf{u}$  ,  $\mathbf{u}$  , and a large preceding in  $\mathbf{u}$  , and a large preceding in  $\mathbf{u}$ negative representer, in a line represented distribution po poddition results (r = n) at the exposure submitted  $W$ .

D.3 .2 .1 .3 The mean time to steril ity, UHSK, is calculated us ing Formula (D .14) :

$$
U_{\text{HSK}} = U_k - \frac{d}{2} - \frac{d}{n} \sum_{i=1}^{k-1} r_i
$$
 (D.14)

where

 $\sim$  11.91. The mean time time time to show the state  $\sim$ 

 $U_k$ is the first exposure to show no growth of the replicates;

 $d$  is the time or dose interval between exposures (being identical);

n is the number of replicates at each exposure (identical number at each exposure, e.g. 20);

r<sup>i</sup> <sup>∑</sup> is the sum of the negatives between U<sup>2</sup> and Uk−1 inclus ive . **D.3.2.1.4** The mean *D* value, *D*, can be calculated using Formula (D.15):

$$
\overline{D} = \frac{U_{\text{HSK}}}{\log_{10} N_0 + 0.250 \text{ 7}} \tag{D.15}
$$

**NOTE** When following the method above, the LHSK procedure makes it possible to calculate the variance, V, the standard deviation (SD) and the 95 % confidence interval (the upper and lower confidence limits).

**D.3.2.1.5** The variance, *V*, is calculated using **Formula** ( $D.16$ ):

$$
V = \frac{d^2}{n^2(n-1)} \sum_{i=1}^{k-1} r_i (n-r_i)
$$
 (D.16)

**D.3.2.1.6** The standard deviation (SD) is calculated using Formula (D.17):

$$
SD = \sqrt{V} \tag{D.17}
$$

D.3 .2 .1 .7 The 95 % confidence interval for D (p = 0 ,05 ) , Dcalc, is calculated us ing Formula (D .18 ) :

$$
D_{\text{calc}} = D \pm 2SD \tag{D.18}
$$

**D.3.2.1.8** D lower confidence limit

$$
= \frac{U_{\text{HSK}} - 2\text{SD}}{\log_{10} N_0 + 0{,}250 \text{ 7}}
$$

**D.3.2.1.9** *D* upper confidence limit

$$
= \frac{U_{\text{HSK}} + 2SD}{\log_{10} N_0 + 0{,}250 \, 7}
$$

#### D.3 .2 .2 Example calculations of the Limited Holcomb-Spearman-Karber procedure (LHSKP)

Examples of calculation of the LHSKP are given in Table D.4.

#### Table D.4 – Examples of data with constant time intervals and constant number of samples



The test is variety where are no negative representative represents the preceding  $\mathbb{P}^1$  at the exposure preceding ing under preceding  $\mathbb{P}^1$  , and a large negative represents , in a linear report from the export report of the control of the exponent to under the expo

**D.3.2.2.1** The *D* value is calculated using **Formula**  $(D.19)$ :

$$
\overline{D} = \frac{U_{\text{HSK}}}{\log_{10} N_0 + 0.250 \, 7} \tag{D.19}
$$

where

$$
N_0 = 1 \times 10^6
$$

D.3 .2 .2 .2 The mean exposure time UHSK required to obtain no growth (sterility) is calculated us ing Formula (D.20):

$$
U_{\text{HSK}} = U_k - \frac{d}{2} - \frac{d}{n} \sum_{i=1}^{k-1} r_i
$$
 (D.20)

where

- $U_k$  $= 30;$
- $d = 2$ ;
- $n = 20;$

 $U_{\rm HSK}$  = 30 –  $=$ − <del>2</del> × (0 + 0 + 1 + 7 + 15 + 19) = 24 ,8 ;

$$
\frac{1}{D} = \frac{24.8}{6,000 + 0,2507} = 3,97 \text{ min (rounded to one decimal place } D = 4,0 \text{ min}).
$$

**D.3.2.2.3** The variance, *V*, is calculated using **Formula**  $(D.21)$ :

$$
V = \frac{d^2}{n^2(n-1)} \sum_{i=1}^{k-1} r_i(n-r_i) = \frac{2^2}{(20)^2(20-1)} \times \left[ \left( 1 \times 19 \right) + \left( 7 \times 13 \right) + \left( 15 \times 5 \right) + \left( 19 \times 1 \right) \right] = 0,1074 \quad \text{(D.21)}
$$

**D.3.2.2.4** The standard deviation (SD) is calculated using Formula (D.22):

$$
SD = \sqrt{V}
$$
  
SD =  $\sqrt{0,1074} = 0,3277$  (D.22)

D.3 .2 .2 .5 The 95 % confidence intervals for D (p = 0 ,05 ) , Dcalc, is calculated us ing Formula (D .2 3 ) :

$$
D_{\text{calc}} = \overline{D} \pm 2\text{SD} \tag{D.23}
$$

*D* lower confidence limit = 
$$
\frac{U_{\text{HSK}} - 2SD}{\log_{10} N_0 + 0,2507}
$$

$$
= \frac{24,8 - (2 \times 0,3227)}{6,000 + 0,2507} = \frac{24,144}{6,2507} = 3,86 \text{ min}
$$

<span id="page-37-0"></span>D upper confidence limit = 
$$
\frac{U_{\text{HSK}} + 2SD}{\log_{10} N_0 + 0.2507} = \frac{24.8 + (2 \times 0.3227)}{6.000 + 0.2507} = \frac{25,455}{6,2507} = 4,07 \text{ min}
$$

where

 $N_{\rm U}$  = 1  $\sim$  10  $^{-1}$ 

### D.3 .3 The Stumbo-Murphy-Cochran-Procedure (SMCP)

### D.3 .3 .1 Procedure

**D.3.3.1.1** Other methods of analysing fraction negative data may be used when equivalence with the methods of  $D<sub>0.3.1</sub>$  and  $D<sub>0.3.2</sub>$  is demonstrated.

**D.3.3.1.2** SMCP, a most probable number (MPN) method, can be practical to use when the response characteristics are predictable.

**D.3.3.1.3** The formula for SMCP requires one result in the fraction negative range consisting of time,  $t$ , the number of units negative for growth,  $r$ , the number of replicates,  $n$ , at one exposure time within the fraction negative range and the initial number of m icroorganisms per rep l icate , N0.

**D.3.3.1.4** To obtain valid data using SMCP, the D value should be calculated as the average of at least three runs in the fraction negative range in order to confirm reproducibility.

**D.3.3.1.5** The same materials apply as those in  $D.2$ .

**D.3.3.1.6** For a confidence interval of 95 %, not less than 50 replicates at each exposure condition shall be used and the condition  $r/n$  less than 0,9 shall be met in order to establish test criteria equivalent to D.3.1 and D.3.2. Test samples shall be subjected to a defined exposure condition within the survival/kill window of the batch/lot.

### D.3 .3 .2 Calculations using the Stumbo -Murphy-Cochran-Procedure

**D.3.3.2.1** The *D* value is calculated using Formula  $(D.24)$ :

$$
D = \frac{t}{\log_{10} A - \log_{10} B} \tag{D.24}
$$

where

 $t$  is the exposure time;

log<sup>10</sup> <sup>A</sup> is the log<sup>10</sup> of in itia l popu lation , N0, per rep l icate ;

 $\sim$  and  $\sim$  is the logical of population at the logic  $\sim$   $\sim$ 

**D.3.3.2.2** Formula (D.24) can be restated for fraction negative data sets:

$$
D = \frac{t}{\log_{10} N_0 - \log_{10} \left[ \ln \left( \frac{n}{r} \right) \right]}
$$

or

$$
D = \frac{t}{\log_{10} N_0 - \log_{10} N_{\mu_i}}
$$

where

log<sup>10</sup> Nμ<sup>i</sup> = log<sup>10</sup> ( ln n/r) or log<sup>10</sup> [2 ,303 log<sup>10</sup> (n/r) ]

- $Nu<sub>i</sub>$ is the natural log of the quotient of the number of replicates per test divided by the number of negative samples;
- $n$  is the number of replicates per exposure time;
- $r$  is the number of units sterile or showing no growth.

D.3 .3 .2 .3 The 95 % confidence interval for D (p = 0 ,05 ) , Dcalc, is calculated us ing Formula (D .2 5 ) :

$$
D_{\text{calc}} = \frac{t}{\log_{10} N_0 - \log_{10} \left( \ln \frac{1}{a} \right)}
$$
 (D.25)

whe

$$
a = \frac{r}{n} \pm 1,96 \sqrt{\frac{r}{n} + \frac{1-r/n}{n}}
$$

**D.3.3.2.4** Formula (D.25) can only be used if  $n \times$  -. <u>. . . .</u> — is greater than or equal to 0,9.

### D.3.3.3 Example calculations of SMCP

### Table  $D.5 -$  Calculations of D value using only one data set in the fraction negative range



**D.3.3.3.1** The *D* value is calculated using Formula (D.26):

$$
D = \frac{t}{\log_{10} A - \log_{10} B} \tag{D.26}
$$

### ISO 11138-1 :2017(E)

#### where

 $t$  is the exposure time;

 $N<sub>0</sub>$ is the initial viable count per test organism per sample =  $1 \times 10^6$ ;

log<sup>10</sup> <sup>A</sup> = log<sup>10</sup> of in itia l popu lation , N0, per samp le ;

 $\sim$  010  $\sim$  -  $\sim$  010  $\sim$  population at the population after exposure time , the set

### or

= log<sup>10</sup> ( ln n/r) or log<sup>10</sup> [2 ,303 log<sup>10</sup> (n/r) ] ;

- $n$  is the number of replicates per exposure time;
- $r$  is the number of units sterile or showing no growth.

$$
D = \frac{24}{6000 - \log_{10} (\ln 2, 7027)}
$$
  
\n
$$
D = \frac{24}{6000 - \log_{10} (0, 9943)}
$$
  
\n
$$
D = \frac{24}{6000 - (-0, 0025)}
$$
  
\n
$$
D = \frac{24}{60000 - 6000} = 4,00 \text{ min (rounded to one decimal place } D = 4,0 \text{ min)}
$$

 $D = 12.1$  . The  $\alpha = 0$  confidence interval for  $D = (p - 0.05)$  ,  $D = 0$  ,  $D = 0$ If  $n \times \cdot$   $\frac{1}{\sqrt{1-\frac{1}{2}}}\cdot$ —– is greater than or equal to 0,9, then the 95 % confidence interval can be calculated using

Formulae  $(D.27)$  and  $(D.28)$ :

D lower confidence limit = 
$$
\frac{t}{\log N_0 - \log_{10}(\ln 1 / a)}
$$
 (D.27)

where

$$
a = \frac{r}{n} + 1,96\sqrt{\frac{r}{n} \times \frac{1 - \frac{r}{n}}{n}}
$$
  

$$
D_{\text{calc}} = \frac{24}{6,000 - \log_{10}(\ln 1 / a)}
$$

where

$$
a = \frac{37}{100} + 1,96\sqrt{\frac{37}{100} \times \frac{1 - 37 / 100}{100}}
$$

<span id="page-40-0"></span>
$$
= 0,37 + 1,96\sqrt{0,37 \times \frac{0,63}{100}}
$$

$$
= 0,37 + 1,96\sqrt{0,37 \times 0,0063}
$$

$$
= 0,37 + 1,96\sqrt{0,002331}
$$

$$
= 0,37 + 1,96 \times 0,04828
$$

$$
a = 0,465
$$

$$
D_{\text{calc}} = \frac{24}{6,000 - \log_{10} \left( \ln \frac{1}{0,465} \right)}
$$
\n
$$
= \frac{24}{6,000 - \log_{10} \left( 0,765 \, 7 \right)}
$$
\n
$$
= \frac{24}{6,000 - \left( -0,115 \, 9 \right)}
$$
\n
$$
= \frac{24}{6,000 + 0,115 \, 9}
$$
\n
$$
D_{\text{calc}} = \frac{24}{6,115 \, 9} = 3,92
$$

*D* upper confidence limit = 
$$
\frac{t}{\log_{10} N_0 - \log_{10} (\ln 1 / a)}
$$
 (D.28)

where

$$
a = \frac{r}{n} - 1,96\sqrt{\frac{r}{n} \times \frac{1 - \frac{r}{n}}{n}}
$$
  

$$
D_{\text{calc}} = \frac{24}{6,000 - \log_{10}(\ln 1 / a)}
$$

where

$$
a = \frac{37}{100} - 1,96\sqrt{\frac{37}{100} \times \frac{1 - 37 / 100}{100}}
$$
  
= 0,37 - 1,96 \sqrt{0,37 \times \frac{0,63}{100}}  
= 0,37 - 1,96 \sqrt{0,37 \times 0,0063}  
= 0,37 - 1,96 \sqrt{0,002331}

$$
= 0,37 - 1,96 \times 0,04828
$$
\n
$$
a = 0,37 - 0,095 = 0,275
$$
\n
$$
D_{\text{calc}} = \frac{24}{6,000 - \log_{10} \left( \ln \frac{1}{0,275} \right)}
$$
\n
$$
= \frac{24}{6,000 - \log_{10} (1,291)}
$$
\n
$$
= \frac{24}{6,000 - 0,111}
$$

$$
D_{\text{calc}} = \frac{24}{5,889} = 4,08
$$

#### **Annex E** Annex E (normative)

# Survival-kill response characteristics

## <span id="page-42-0"></span>E.1 Principle

Monitoring the survival-kill response characteristics of a lot/batch of biological indicators provides an additional means of ensuring the consistent performance of units within a given lot/batch.

In the following subclauses and formulae of this annex, the variable " $t$ " can be replaced by any other **NOTE** process variable used to calculate the  $D$  value.

### E.2 Materials

**E.2.1** Test samples shall be representative of spore suspensions, inoculated carriers or packaged biological indicators.

**E.2.2** The relevant resistometer shall be used.

**NOTE** Test methods are given in relevant parts of ISO 11138. Specifications for resistometers are given in ISO 18472 .

 $E.2.3$ The incubator shall be set to provide, and monitored to confirm, the temperature specified in the culture conditions. culture conditions .

 $E.2.4$ The growth medium shall be as specified in the culture conditions.

### \_\_\_\_\_\_\_\_\_\_\_\_

**E.3.1** Not less than 50 replicates shall be used to confirm both the survival time and the kill time (see Table 2). The D value calculated by survivor curve method (see [Annex C](#page-22-0)) or a fraction negative method (see  $Annex D$ ) shall be used for the stipulation of the survival-kill response characteristics.

For lots with a single negative biological indicator in a survival test, or a single positive BI in a kill test, an additional 100 samples (minimum) may be tested. If no additional unexpected results are obtained, the survival and kill times are confirmed.

**E.3.2** Samples shall be cultured after exposure according to the manufacturer's specified method.

**E.3.3** The survival performance is the labelled exposure time that results in surviving test organisms for each biological indicator. The kill performance is the labelled exposure time that results in kill of all test organisms of each biological indicator.

E.3.4 Survival-kill performance characteristics shall be determined in a resistometer using the relevant resistometer process parameters.

**NOTE** Reference conditions for specific sterilization processes are provided in relevant parts of ISO 11138. E.3.5 Relevant values for survival time and kill time can be obtained by using the following formulae:

surviva lation = not less than ( log10 nomence population = 2 ) = 2 month,

king than  $\mathcal{L} = \{ \mathcal{L} \mid \mathcal{L} = \mathcal{L} \}$  . The more independent of  $\mathcal{L} = \{ \mathcal{L} \}$ 

**E.3.6** The number of units run per exposure will depend on both the capacity and the operating characteristics of the resistometer being used. It might be necessary to run several exposures at both the survival and kill times in order to test the total number of units required.

# Annex F (informative)

# <span id="page-44-0"></span>Relationship between components of biological indicators



### Table F.1 — Relationship between components of biological indicators

<sup>a</sup> The fluid employed can vary depending on whether the microorganisms are to be held for storage purposes or employed for testing purposes.

<sup>b</sup> Can be defined as a biological indicator if used to monitor a sterilization process.

In some instances the surface can be product for testing purposes.

## **Bibliography**

- <span id="page-45-0"></span>[1] ISO 8601, Data elements and interchange formats — Information interchange — Representation of dates and times
- [2] ISO/TS 11139:2006, Sterilization of health care products Vocabulary
- [3] ISO 11140-1, Sterilization of health care products Chemical indicators Part 1: General requirements
- $[4]$  ISO 13485, Medical devices  $-$  Quality management systems  $-$  Requirements for regulatory purposes
- [5] ISO 14161:2009, Sterilization of health care products Biological indicators Guidance for the selection, use and interpretation of results
- [6] ISO 15223-1, Medical devices Symbols to be used with medical device labels, labelling and information to be supplied  $-$  Part 1: General requirements
- [7] ISO 80000 (all parts), Quantities and units
- [8] IEC 60027 (all parts), Letter symbols to be used in electrical technology
- [9] ARMITAGE P., & ALLEN I. Methods of Estimating the LD 50 in Quantal Response Data. *J. Hyg.* (Lond.). 1950, XLVIII pp. 298-322
- [10] COCHRAN W.G. Estimation of Bacterial Densities by Means of the "Most Probable Number". Biometrics. 1950, 6 (1) pp. 105-116
- [11] FRITZE AND PUKALL. Int. J. Syst. Evol. Microbiol. 2001, 51 pp. 35–37
- [12] GADDUM J.H. Reports on biological standards, III, Methods of biological assay depending on a quantal response, Spec. Rep. Ser. Med. Res. Council, London, No. 183, 1933
- [13] MORRISSEY R.F., & PHILLIPS G.B. eds. Graham, G.S. and C.A., Boris, Chemical and Biological Indicators, Sterilization technology: A Practical Guide for Manufacturers and Users of Health care Products. Van Nostrand Reinhold, NY, 1993
- [14] HALVORSON H.O., & ZIEGLER N.R. Application of statistics to problems in bacteriology. J. Bacteriol. 1933, 25 pp. 101-121
- [15] Holcomb R.G., & Pflug I.J. The Spearman-Karber method of analyzing quantal assay microbial destruction data. In: Selected Papers on the Microbiology and Engineering of Sterilization Processes, (PFLUG I.J. ed.). Environmental Sterilization Laboratory, Minneapolis, Fifth Edition, 1988, pp. 83-100.
- [16] JOHNSON E.A., & BROWN B.Wm. The Spearman Estimator for Serial Dilutions Assays. Biometrics. 1961, 17 pp. 79-88
- [17] Lewis J.C. The Estimation of Decimal Reduction Times. Appl. Micro. 1956, 4 pp. 211-221
- [18] Moslack G.A., & Gillis J.R. Operating Precision of Steam BIER vessels and the Interactive Effects of varying Z Valves on the Reproducibility of Listed D Values. PDA J. Pharm. Sci. Technol. 2002, 56 (6) pp. 318-331
- [19] Mosley G.A. Estimating the Effects of EtO BIER-Vessel Operating Precision on D Value Calculations.  $M D & D I$ . 2002, 24 (4) pp. 46-52
- [20] Mosley G.A., Gillis J., Whitbourne J. Calculating Equivalent Time for Use in Determining the Lethality of EtO Sterilization Processes. M D & D I. 2002, 24 (2) pp. 54–63
- [21] PFLUG I.J., HOLCOMB R.G., GOMEZ M.M. Thermal Destruction of Microorganisms. In: Disinfection, Sterilization and Preservation, (BLOCK S.S. ed.). Lippincott, Williams & Wilkins, Philadelphia, 2001, pp. 79-129.
- [22] PFLUG I.J. Microbiology and Engineering of Sterilization Processes. Environmental Sterilization Services, Minneapolis, Eleventh Edition, 2003
- [23] PFLUG I.J. Microbiology and Engineering of Sterilization Processes, St. Paul, University of Minnesota, 1992, ISBN 0-929340-01-9
- [24] REED L.J., & MUENCH H.A. Simple Method of Estimating Fifty per cent Endpoints. Am. J. Hyg. 1938, 27 (3) pp. 493-497
- [25] SCHMIDT C.F. Thermal resistance of microorganisms, in Antiseptics, Disinfectants, Fungicides and Sterilization. (G.F. Reddish, ed) 1st., pp. 720-759, Lea and Febiger, Philadelphia
- [26] SPEARMAN C. The method of 'right and wrong cases' ('constant stimuli') without Gauss's formulae. Br. J. Psychol. 1908, 2 p. 227
- [27] STUMBO C.R., MURPHY J.R., COCHRAN J. Nature of Thermal Death Time Curves for P.A. 3679 and Clostridium Botulinum. Food Technol. 1950, 4 pp. 321-326
- [28] WORLD HEALTH ORGANIZATION, LABORATORY BIOSAFETY MANUAL, THIRD EDITION. WHO, Geneva, 2004 ISBN 92 4 154650 6
- [29] United States Pharmacopoeia, official revision and Monographs for specific BIs; <55>, Biological Indicators — Resistance Performance Tests: <1035> Biological Indicators for Sterilization

ISO 11138-1 :2017(E)

## ICS 11.080.01 Price based on 41 pages

 $\equiv$ 

 $\copyright$  ISO 2017 – All rights reserved

 $=$